The Pharmacokinetics, Pharmacodynamics, Tolerability, and Safety of Orally Dosed QY201, a Novel JAK1/TYK2 Inhibitor, in Chinese Healthy Subjects
The Journal of Clinical Pharmacology · 2025
DOI: 10.1002/jcph.70053 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Clinical Pharmacology, 2025. Verfasst von Jia-Ying Wang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Center of Clinical Pharmacology, The Second Affiliated Hospital of Zhejiang University, School of Medicine, Hangzhou, Zhejiang, China. Hauptthemen laut MEDLINE: Janus Kinase 1, Protein Kinase Inhibitors. Die Arbeit nennt 21 Literaturangaben. Gefördert von: National Major Science and Technology Project of China, E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd, National Major Science and Technology Projects of China.
Abstract (Originalsprache)
QY201 is a dual inhibitor targeting Janus Kinase 1/Tyrosine Kinase 2, developed for the treatment of atopic dermatitis and other autoimmune diseases. The pharmacokinetics (PK), pharmacodynamics (PD), tolerability, and safety of QY201 were assessed in a randomized, double‐blind study in healthy subjects. Population PK and PD models were developed to characterize the PK and PD of QY201. QY201 was absorbed and eliminated rapidly, and the exposure was approximately dose‐proportional over the 1‐40 mg dose range, with no significant accumulation after repeated dosing. A high‐fat meal reduced the maximum plasma concentration of QY201 by 40.7% but did not affect the area under the concentration‐time curve. The fraction of the QY201 dose eliminated in the urine unchanged was 22%. In the multiple ascending‐dose phase, the reduction of hypersensitive C‐reactive protein (hsCRP) and absolute neutrophil count (ANC) showed dose‐dependent trends within certain doses. The PK of QY201 was best described by a 2‐compartment model with first‐order absorption and elimination. The hsCRP was best described by an indirect response maximum drug effect (E max ) model. QY201 was generally safe and well tolerated following oral administration, with dose‐limiting toxicity of the highest tested dose of 40 mg being well tolerated. The favorable PK, PD, safety, and tolerability results from these studies supported evaluations of QY201 in future clinical trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center of Clinical Pharmacology, The Second Affiliated Hospital of Zhejiang University, School of Medicine, Hangzhou, Zhejiang, China.
- E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd, Hangzhou, Zhejiang, China.
- Betta Pharmaceuticals Co., Ltd, Hangzhou, Zhejiang, China.
Förderung
- National Major Science and Technology Project of China
- E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd
- National Major Science and Technology Projects of China
Zitieren
APA
Wang, J. Y., Gao, Y. H., Ruan, Z. R., Yang, D. D., Li, H., Qiao, S. D., Li, J. H., You, X., Shi, J., & Jiang, B. (2025). The Pharmacokinetics, Pharmacodynamics, Tolerability, and Safety of Orally Dosed QY201, a Novel JAK1/TYK2 Inhibitor, in Chinese Healthy Subjects. The Journal of Clinical Pharmacology. https://doi.org/10.1002/jcph.70053
Vancouver
Wang JY, Gao YH, Ruan ZR, Yang DD, Li H, Qiao SD, et al. The Pharmacokinetics, Pharmacodynamics, Tolerability, and Safety of Orally Dosed QY201, a Novel JAK1/TYK2 Inhibitor, in Chinese Healthy Subjects. The Journal of Clinical Pharmacology. 2025. doi:10.1002/jcph.70053
BibTeX
@article{Wang2025,
author = {Wang, Jia-Ying and Gao, Ying-Hui and Ruan, Zou-Rong and Yang, Dan-Dan and Li, Hua and Qiao, Shi-da and Li, Jian-Hui and You, Xin and Shi, Jun and Jiang, Bo},
title = {The Pharmacokinetics, Pharmacodynamics, Tolerability, and Safety of Orally Dosed QY201, a Novel JAK1/TYK2 Inhibitor, in Chinese Healthy Subjects},
journal = {The Journal of Clinical Pharmacology},
year = {2025},
doi = {10.1002/jcph.70053}
}
EUVIMED